Background therapy
Sponsors
Sanofi, Boehringer Ingelheim, Alexion Pharmaceuticals, Inc., Lyra Therapeutics
Conditions
Chronic Rhinosinusitis (Diagnosis)Chronic SinusitisDiabetes Mellitus, Type 2Immunoglobulin A NephropathyLupus NephritisType 1 Diabetes MellitusType 2 Diabetes Mellitus
Phase 2
Phase 3
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
CompletedNCT02320721
Start: 2015-01-31End: 2016-05-31Updated: 2020-04-21
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
CompletedNCT02735044
Start: 2016-04-14End: 2018-12-20Updated: 2022-03-25
Linagliptin Add-on to Insulin Background Therapy
CompletedNCT02897349
Start: 2016-09-30End: 2019-01-18Updated: 2020-03-25
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
TerminatedNCT03434119
Start: 2018-02-20End: 2019-01-07Updated: 2022-03-28
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
TerminatedNCT03713684
Start: 2018-11-09End: 2021-01-04Updated: 2021-12-02
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
CompletedNCT05219968
Start: 2022-01-27End: 2024-09-16Updated: 2025-05-02
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
CompletedNCT05295459
Start: 2022-05-13End: 2025-04-02Updated: 2026-02-19